Form 4: Kura Oncology CCO Sells Shares for Tax Obligations

Kura Oncology's Chief Commercial Officer, Brian T. Powl, sold 6,414 shares of common stock on January 27, 2026, to cover tax liabilities from RSU vesting.

Summary

• Brian T. Powl, Chief Commercial Officer of Kura Oncology, Inc., reported the sale of 6,414 shares of common stock.
• The transactions occurred on January 27, 2026, and were made pursuant to a Rule 10b5-1(c) plan.
• The sales were 'sell-to-cover' transactions to satisfy tax obligations related to the vesting of Restricted Stock Units (RSUs).
• Specifically, 4,842 shares were sold at $8.4606 per share for taxes on an RSU vesting dated January 2, 2025.
• An additional 1,572 shares were sold at $8.4607 per share for taxes on an RSU vesting dated January 2, 2024.
• Following these transactions, Mr. Powl beneficially owns 183,275 shares of Kura Oncology common stock.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' for tax purposes, which is a neutral event and does not reflect a change in management's confidence or the company's prospects. It was also conducted under a pre-arranged 10b5-1 plan.

Future Outlook

The filing does not contain any forward-looking statements or guidance beyond the reported transactions.

Industry Context

This Form 4 filing reports a routine insider transaction (sell-to-cover) and does not provide information relevant to broader industry trends or competitive analysis.

Stakeholder Impact

• The impact on shareholders is minimal as this is a routine, non-discretionary sale to cover tax liabilities from RSU vesting.
• The transaction does not indicate any change in the company's operational or financial health.

Key Dates

Recommendation

The reported insider transaction is a routine 'sell-to-cover' to satisfy tax obligations upon RSU vesting, executed under a pre-arranged 10b5-1 plan. This type of transaction is non-discretionary and does not typically signal a change in the insider's view of the company's future prospects. Therefore, it provides no new fundamental information to warrant a change in investment recommendation, suggesting a 'hold' position based solely on this filing.

Keywords

Kura Oncology, KURA, Brian T. Powl, Chief Commercial Officer, CCO, Insider Trading, Form 4, Stock Sale, RSU Vesting, Sell-to-Cover, Equity Compensation, Rule 10b5-1